MAFP

CAS# 188404-10-6

MAFP

Catalog No. BCC7059----Order now to get a substantial discount!

Product Name & Size Price Stock
MAFP: 5mg $161 In Stock
MAFP: 10mg Please Inquire In Stock
MAFP: 20mg Please Inquire Please Inquire
MAFP: 50mg Please Inquire Please Inquire
MAFP: 100mg Please Inquire Please Inquire
MAFP: 200mg Please Inquire Please Inquire
MAFP: 500mg Please Inquire Please Inquire
MAFP: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of MAFP

Number of papers citing our products

Chemical structure

MAFP

3D structure

Chemical Properties of MAFP

Cas No. 188404-10-6 SDF Download SDF
PubChem ID 10429254 Appearance Powder
Formula C21H36FO2P M.Wt 370.49
Type of Compound N/A Storage Desiccate at -20°C
Solubility Methyl Acetate : ≥ 10 mg/mL (26.99 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene
SMILES CCCCCC=CCC=CCC=CCC=CCCCCP(=O)(OC)F
Standard InChIKey KWKZCGMJGHHOKJ-ZKWNWVNESA-N
Standard InChI InChI=1S/C21H36FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of MAFP

DescriptionPotent, irreversible inhibitor of fatty acid amide hydrolase (FAAH, anandamide amidase), the enzyme responsible for anandamide hydrolysis (IC50 = 2.5 nM). Also binds irreversibly to CB1 receptors (IC50 = 20 nM).

MAFP Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

MAFP Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of MAFP

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6991 mL 13.4956 mL 26.9913 mL 53.9826 mL 67.4782 mL
5 mM 0.5398 mL 2.6991 mL 5.3983 mL 10.7965 mL 13.4956 mL
10 mM 0.2699 mL 1.3496 mL 2.6991 mL 5.3983 mL 6.7478 mL
50 mM 0.054 mL 0.2699 mL 0.5398 mL 1.0797 mL 1.3496 mL
100 mM 0.027 mL 0.135 mL 0.2699 mL 0.5398 mL 0.6748 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on MAFP

Inhibition of phospholipase A1, lipase and galactolipase activities of pancreatic lipase-related protein 2 by methyl arachidonyl fluorophosphonate (MAFP).[Pubmed:22835523]

Biochim Biophys Acta. 2012 Nov;1821(11):1379-85.

Methyl arachidonyl fluorophosphonate (MAFP) is a known inhibitor of cytosolic phospholipase A2 and some other serine enzymes. MAFP was found here to be an irreversible inhibitor of human pancreatic lipase-related protein 2 (HPLRP2), an enzyme displaying lipase, phospholipase A1 and galactolipase activities. In the presence of MAFP, mass spectrometry analysis of HPLRP2 revealed a mass increase of 351Da, suggesting a covalent binding of MAFP to the active site serine residue. When HPLRP2 was pre-incubated with MAFP before measuring residual activity, a direct inhibition of HPLRP2 occurred, confirming that HPLRP2 has an active site freely accessible to solvent and differs from most lipases in solution. HPLRP2 activities on tributyrin (TC4), phosphatidylcholine (PC) and monogalactosyl dioctanoylglycerol (C8-MGDG) were equally inhibited under these conditions. Bile salts were not required to trigger the inhibition, but they significantly increased the rate of HPLRP2 inhibition, probably because of MAFP micellar solubilization. Since HPLRP2 is active on various substrates that self-organize differently in the presence of water, HPLRP2 inhibition by MAFP was tested in the presence of these substrates after adding MAFP in the course of the lipolysis reaction. In this case, the rates of inhibition of lipase, phospholipase A1 and galactolipase activities were not equivalent (triglycerides>PC>MGDG), suggesting different enzyme/inhibitor partitioning between the aqueous phase and lipid aggregates. The inhibition by MAFP of a well identified phospholipase A1 (HPLRP2), present in pancreatic juice and also in human monocytes, indicates that MAFP cannot be used for discriminating phospholipase A2 from A1 activities at the cellular level.

[Dendritic cell vaccine modified by murine mAFP gene enhances immunoprotective effect on liver carcinogenesis and tumor development in mice].[Pubmed:18788625]

Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):250-4.

OBJECTIVE: To construct a dendritic cell vaccine transduced by murine alpha-fetoprotein (MAFP) gene, and evaluate its immunoprotective effect on C57BL/6J mice during the induction of hepatocellular carcinoma by diethylnitrosamines, carbon tetrachloride and ethanol. METHODS: Dendritic cells (DCs) were induced and augmented by murine IL-4 and GM-CSF, and transfected by recombinant adenovirus engineered with MAFP gene. Major MHC class I and II, B7.1 (CD80), B7.2 (CD86), CD18a, and CD54 molecules on DC were analyzed by FACS. 80 C57BL/6J male mice were randomly divided into 4 groups (20 mice per group): Simple DC inoculated group, pAdBM5-MAFP-DC inoculated group, pAdBM5-MAFP plasmid inoculated group, and PBS control group. They were immunized once with 5 x 10(5) DCs (0.1 ml)/mouse administered s. c. in the left flank or 100 mg pAdBMS-MAFP plasmid/mouse administered i. m. in the left tibialis anterior muscle. Inoculation was conducted once a week for 4 weeks after 3 times consecutive immunization initially. At the same time of immunization, DEN/CCl4/ethanol were given to induce hepatocellular carcinoma. Tumor incidence was assessed after 20 weeks. RESULTS: A transgenic DC vaccine was successfully constructed and the MAFP transgenic DCs expressed high level molecules of major MHC class I and II , B7.1, B7.2, CD18a, and CD54. After the 20-week induction, the incidence of primary hepatocellular carcinoma (PLC) was 70.0% in simple DC inoculated group, 25.0% in pAdBMS-MAFP-DC inoculated group, 65.0% in pAdBM5-MAFP plasmid inoculated group, and 75.0% in PBS control group. There was a significant difference between group B and other groups (P < 0.05). CONCLUSION: MAFP transgenic DC tumor vaccine inoculation may induce strong immunoprotection against liver carcinogenesis and tumor development and reduce PLC incidence induced by DEN/CCl4/ethanol.

Description

MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of cPLA2 and iPLA2. MAFP is also a potent irreversible inhibitor of anandamide amidase.

Keywords:

MAFP,188404-10-6,Natural Products,Cannabinoid Receptor, buy MAFP , MAFP supplier , purchase MAFP , MAFP cost , MAFP manufacturer , order MAFP , high purity MAFP

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: